A phase I dose-escalation study of a first-in-class HIF1 and HIF2 dual inhibitor R01 in patients with advanced tumors. A novel co-culture system to validate results of a phase I trial testing new ...
The FDA put out a safety communication Tuesday warning about the possibility of “serious complications” tied to the use of Hologic’s BioZorb devices. The coil-shaped markers are implanted in soft ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback